Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes after resting full-cycle ratio and deferral of revascularization.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Modified essential frailty toolset for risk stratification in transcatheter mitral and tricuspid valve repair.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Effect of baroreflex activation therapy on home blood pressure measurements after long-term treatment - a prospective, randomized crossover study.

Journal of hypertension·2026
Same author

Bailout PASCAL Implantation for Salvation of Iatrogenic Leaflet Perforation During Transcatheter Edge-to-Edge Repair.

JACC. Cardiovascular interventions·2026
Same author

A Simplified Frailty Measure Improves Risk Stratification in Patients Undergoing Percutaneous Mitral Valve Repair.

Journal of cachexia, sarcopenia and muscle·2025
Same author

[Treatment Algorithm of Pulmonary Arterial Hypertension].

Pneumologie (Stuttgart, Germany)·2025
Same journal

Clinical outcomes of intravascular imaging-guided versus angiography-guided drug-coated balloon angioplasty for de novo coronary lesions.

International journal of cardiology·2026
Same journal

Hypertension management in obstructive hypertrophic cardiomyopathy patients treated with cardiac myosin inhibitors - real world data.

International journal of cardiology·2026
Same journal

Fully quantitative CMR rest perfusion reveals myocardial perfusion abnormality in Kawasaki disease: Association with left ventricular Remodeling.

International journal of cardiology·2026
Same journal

Predicted adherence and ischaemic stroke risk in atrial fibrillation patients initiating oral anticoagulation: A cohort study of the medication adherence score.

International journal of cardiology·2026
Same journal

Severe tricuspid regurgitation is a congestion-driven cardiorenal disease: A longitudinal study defining a right heart failure phenotype.

International journal of cardiology·2026
Same journal

Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.

International journal of cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

Hyperaldosteronism is associated with a decrease in number and altered growth factor expression of endothelial

Dennis Ladage1, Nora Schützeberg2, Theresa Dartsch1

  • 1Laboratory of Muscle Research and Molecular Cardiology, Dept. III of Internal Medicine, University of Cologne, Cologne, Germany.

International Journal of Cardiology
|February 2, 2010
PubMed
Summary
This summary is machine-generated.

High aldosterone levels reduce endothelial progenitor cells (EPCs), crucial for blood vessel repair. Spironolactone treatment reversed this effect, suggesting potential for cell-based therapies.

More Related Videos

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
04:33

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions

Published on: March 12, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
04:33

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions

Published on: March 12, 2019

Area of Science:

  • Cardiovascular Biology
  • Endothelial Cell Research
  • Regenerative Medicine

Background:

  • Aldosterone is implicated in hypertension, heart failure, and vascular damage.
  • Endothelial progenitor cells (EPCs) are vital for repairing damaged blood vessels.
  • The impact of aldosterone on EPCs in vivo remains largely unexplored.

Purpose of the Study:

  • To investigate the long-term effects of aldosterone on the number and function of EPCs in vivo.
  • To determine if spironolactone, an aldosterone antagonist, can counteract aldosterone-induced changes in EPCs.

Main Methods:

  • Male Wistar rats received aldosterone or placebo via subcutaneous pumps for 28 days.
  • Animals were treated with or without spironolactone.
  • EPCs were identified and quantified; gene expression of VEGF receptor, VEGF, HGF, SDF1, and mineralocorticoid receptor (MR) was analyzed via qPCR.
  • Serum VEGF levels were measured using ELISA.

Main Results:

  • Chronic aldosterone treatment significantly reduced the total number of EPCs.
  • Spironolactone administration normalized EPC numbers and, in some cases, increased them above control levels.
  • Aldosterone downregulated HGF, MR2, and VEGF receptor mRNA in EPCs, while SDF1 mRNA remained unaffected.

Conclusions:

  • Elevated aldosterone impairs EPC function and reduces their numbers in vivo.
  • Spironolactone effectively antagonizes the negative effects of aldosterone on EPCs.
  • Mineralocorticoid receptor blockade via spironolactone may enhance outcomes in cell-based therapies for vascular repair.